Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.54 |
| ▸ | GLP1R | P43220 | 14/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.52 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
| ▸ | SCTR | P47872 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461991 | 0.99 | C5AR1 (0.54) | C5AR1GLP1RIL23RTFPI | |
| SCHEMBL30592735 | 0.95 | NPY4R (0.49) | C5AR1GLP1RIL23RTFPI | |
| SCHEMBL31680257 | 0.94 | C5AR1 (0.58) | C5AR1GLP1RIL23RTFPISCTR | |
| SCHEMBL29883702 | 0.90 | NPY4R (0.49) | IL23R | |
| SCHEMBL30463393 | 0.88 | NPY4R (0.52) | — | |
| SCHEMBL29794125 | 0.88 | GLP1R (0.63) | GLP1RSCTR | |
| SCHEMBL29904555 | 0.87 | NPY4R (0.53) | C5AR1IL23R | |
| SCHEMBL30026320 | 0.87 | C5AR1 (0.51) | C5AR1GLP1RIL23R | |
| SCHEMBL30883219 | 0.86 | TFPI (0.67) | GLP1RTFPISCTR | |
| SCHEMBL5500011 | 0.86 | C5AR1 (0.58) | C5AR1GLP1RIL23RTFPISCTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230346874-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20220280593-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11312993-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | CLN6, PRPH, TSG101 | C5AR1 964/4885GLP1R 1554/4885IL23R 3407/4885 |
| US-20220280593-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | RNPEP, TNNI3, BDKRB1 | C5AR1 104/4885GLP1R 222/4885IL23R 1654/4885 |
| US-20230346874-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS | CRYAA, CRYAB, IAPP | C5AR1 264/4885GLP1R 34/4885IL23R 3422/4885 |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | CRYAA, CRYAB, PRPH | C5AR1 760/4885GLP1R 880/4885IL23R 4381/4885 |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | RNPEP, TNNI3, BDKRB1 | C5AR1 104/4885GLP1R 222/4885IL23R 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.